SEC Form 4 · accession 0001133416-26-000057
GALECTIN THERAPEUTICS INC · GALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Khurram Jamil
Officer — Chief Medical Officer
Period of report
Jun 23, 2026
Accepted (ET)
Jun 25, 2026 · 4:06 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001133416
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 23, 2026 | M | 7,557 | $1.23 | A | 7,557 | D | |
| Common StockF2 | Jun 23, 2026 | S | 7,557 | $3.14 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F3 | $1.23 | Jun 23, 2026 | M | 7,557 | D | Dec 31, 2025 | Jan 23, 2035 | Common Stock | 7,557 | 32,500 | D |
Explanation of responses
- F1The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026
- F2The shares were sold in multiple transactions at prices ranging from $3.10 to $3.17. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F3The options vested as follows: 16,250 on each of June 30, 2025, December 31, 2025, June 30, 2026, and December 31, 2026.